Niclosamide Formulations for the Treatment of Influenza Infections

NIH Pandemic-Era Grants

Pandemic Era Grants

2022

↗ Live URL (may be dead)

Document text

Principal Investigator: Gary  Fujii
Organization: MOLECULAR EXPRESS, INC.
Fiscal Year: 2022
Award: $298,479
Funding agency: National Institute of Allergy and Infectious Diseases

Project Summary
 The principal goal of this project is to demonstrate that the FDA-approved anthelminthic drug,
niclosamide, can be reformulated in a synthetic lung surfactant which can be aerosolized for the treatment of
infections caused by respiratory viruses. The studies proposed in this SBIR Phase I application will be focused
on testing this concept by suspending niclosamide loaded liposomes in our proprietary lung surfactant
technology (Niclosurf) and testing candidate Niclosurf formulations in a mouse influenza challenge model. The
effectiveness of Niclosurf as a treatment for respiratory viral infections caused by influenza will be evaluated.

Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><A549><Adenoviridae><Adenoviruses><Adverse reactions><Aerosols><Animals><Anions><Antiviral Agents><Antiviral Drugs><Antivirals><Body Weight decreased><Breakbone Fever Virus><Bronchioalveolar Lavage><Bronchoalveolar Lavage><Bronchopulmonary Lavage><COVID-19 virus><COVID19 virus><Cell Body><Cell Function><Cell Process><Cell physiology><Cells><Cellular Function><Cellular Physiology><Cellular Process><CoV-2><CoV2><Coronaviridae><Coronavirus><Data><Dengue Virus><Dengue fever virus><Disease><Disorder><Dose><Drug Modelings><Drug Screening><Drugs><Effectiveness><Endosomes><Enterovirus><Evaluation><FDA approved><Female><Formulation><Goals><Grippe><H+ element><H1N1><H1N1 Virus><HCV><HeLa><Hela Cells><Hepatitis C virus><Human><Hydrogen Ions><Idiopathic respiratory distress><In Vitro><Infection><Influenza><Influenza A><Influenza A Virus, H1N1 Subtype><Influenza A virus><Influenza Vaccines><Influenza Virus><Influenza Viruses Type A><Influenzavirus A><Inner mitochondrial membrane><LD-50><LD50><Lead><Lethal Dose 50><Lipids><Liposomal><Liposomes><Lung><Lung Lavage><Lung Respiratory System><Lung Surfactant><MERS corona virus><MERS coronavirus><MERS virus><MERS-CoV><Medication><Mice><Mice Mammals><Middle East Respiratory Syndrome Corona Virus><Middle East Respiratory Syndrome Coronavirus><Middle East Respiratory Syndrome Virus><Middle East Respiratory Syndrome-CoV><Middle Eastern Respiratory Syndrome Corona virus><Middle Eastern Respiratory Syndrome Coronavirus><Middle Eastern Respiratory Syndrome Virus><Middle Eastern Respiratory Syndrome-CoV><Modeling><Modern Man><Molecular><Monitor><Morbidity><Morbidity - disease rate><Murine><Mus><NHLBI><NRDS><Nasopharynx><National Heart, Lung, and Blood Institute><Neonatal Respiratory Distress><Newborn RDS><Orthomyxovirus Type A><Patients><Pb element><Pharmaceutic Preparations><Pharmaceutical Preparations><Phase><Premature Infant><Preparation><Production><Property><Proteins><Protons><Pulmonary Surfactants><Receptosomes><Reporting><Research><Respiratory Disease><Respiratory System Disease><Respiratory System Disorder><Respiratory distress><Rhinopharynx><Rhinovirus><SARS Virus><SARS corona virus><SARS corona virus 2><SARS coronavirus><SARS-Associated Coronavirus><SARS-CO-V2><SARS-COVID-2><SARS-CoV><SARS-CoV-1><SARS-CoV-2><SARS-CoV2><SARS-Related Coronavirus><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><SBIR><Severe Acute Respiratory Coronavirus><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome Virus><Severe Acute Respiratory Syndrome corona virus><Severe Acute Respiratory Syndrome coronavirus><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome related corona virus 2><Site><Small Business Innovation Research><Small Business Innovation Research Grant><Standardization><Subcellular Process><Technology><Testing><Time><Type A Influenza><Viral><Viral Burden><Viral Diseases><Viral Load><Viral Load result><Viral Respiratory Tract Infection><Virus><Virus Diseases><Weight Loss><Weight Reduction><Wuhan coronavirus><ZIKV><Zika Virus><absorption><aerosolized><anti-viral agents><anti-viral compound><anti-viral drugs><anti-viral efficacy><anti-viral medication><anti-viral therapeutic><anti-virals><antiviral compound><antiviral efficacy><antiviral medication><antiviral therapeutic><body weight loss><bronchopulmonary lavage therapy><clinical applicability><clinical application><corona virus><coronavirus disease 2019 virus><coronavirus disease-19 virus><delivery vector><delivery vehicle><delta pH><deltapH><drug/agent><flu infection><flu serotype><flu strain><flu subtype><flu vaccine><flu viral strain><flu virus infection><flu virus strain><flu virus vaccine><hCoV19><heavy metal Pb><heavy metal lead><improved><infants born premature><infants born prematurely><infected with flu><infected with flu virus><infected with influenza><infected with influenza virus><influenza infection><influenza serotype><influenza strain><influenza subtype><influenza viral strain><influenza virus infection><influenza virus strain><influenza virus vaccine><influenzavirus><inhibitor><lipid based nanoparticle><lipid nanoparticle><lipophilicity><male group><men's group><nCoV2><nano-molar><nanomolar><nasopharnygeal><neonatal RDS><neonatal respiratory distress syndrome><neonatal surfactant deficiency><newborn idiopathic respiratory distress><newborn pulmonary hypoperfusion syndrome><newborn respiratory distress><newborn respiratory distress syndrome><novel><pH gradient><pandemic><pandemic disease><peptide B><premature baby><premature infant human><preterm baby><preterm infant><preterm infant human><proenkephalin peptide B><professor><prophylactic><public health relevance><pulmonary><respiratory distress at birth><respiratory virus><severe acute respiratory syndrome-CoV><surfactant><vaccine against flu><vaccine against influenza><vaccine formulation><viral infection><viral respiratory infection><virus infection><virus-induced disease><wt-loss><zikav>